Activation of human natural killer cells by the novel innate immune modulator recombinant Eimeria antigen

Human Immunology

Volumn 74, Issue 8, 2013, Pages 916-926

  Aylsworth, Charles F ^a,b   Aldhamen, Yasser A ^a,b   Seregin, Sergey S ^a,b   Godbehere, Sarah ^a,b   Amalfitano, Andrea ^a,b  

^a Michigan State University ^*  (United States)

^b MICHIGAN STATE UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CD69 ANTIGEN; CHEMOKINE; CYTOKINE; GAMMA INTERFERON; GRANZYME B; MYELOID DIFFERENTIATION FACTOR 88; RECOMBINANT ANTIGEN; TOLL LIKE RECEPTOR 11; TOLL LIKE RECEPTOR 12; UNCLASSIFIED DRUG;

ARTICLE; CELL ACTIVATION; CELL CULTURE; CELL LEVEL; EIMERIA; HUMAN; HUMAN CELL; IMMUNOTHERAPY; INFECTION; INNATE IMMUNITY; MONONUCLEAR CELL; NATURAL KILLER CELL; NEOPLASM; NONHUMAN; PRIORITY JOURNAL; TUMOR CELL; UPREGULATION;

ADCC; ANTIBODY DEPENDENT CELL-MEDIATED CYTOTOXICITY; CARBOXYFLUORESCEIN SUCCINIMIDYL ESTER; CFSE; EA; EIMERIA ANTIGEN; FITC; FLUORESCEIN ISOTHIOCYANATE; LACTATE DEHYDROGENASE; LDH; MEAN FLUORESCENCE INTENSITY; MFI; PI; PROPIDIUM IODIDE; REA; RECOMBINANT EA;

ANTIGENS, CD; ANTIGENS, PROTOZOAN; CELLS, CULTURED; CYTOKINES; DENDRITIC CELLS; EIMERIA; GENE EXPRESSION REGULATION; HUMANS; IMMUNITY, INNATE; IMMUNOPHENOTYPING; KILLER CELLS, NATURAL; LEUKOCYTES, MONONUCLEAR; LYMPHOCYTE ACTIVATION; NK CELL LECTIN-LIKE RECEPTOR SUBFAMILY C; PHENOTYPE; RECOMBINANT PROTEINS; TOLL-LIKE RECEPTOR 4; TOLL-LIKE RECEPTOR 7; TOLL-LIKE RECEPTOR 8;

EID: 84879883212     PISSN: 01988859     EISSN: 18791166     Source Type: Journal    
DOI: 10.1016/j.humimm.2013.04.035     Document Type: Article

References (38)

1. Delamarre L., Mellman I. Harnessing dendritic cells for immunotherapy. Semin Immunol 2011, 23:2-11.
2. Riganti C., Massaia M., Davey M.S., Eberl M. Human gammadelta T-cell responses in infection and immunotherapy: common mechanisms, common mediators?. Eur J Immunol 2012, 42:1668-1676.
3. Shook D.R., Campana D. Natural killer cell engineering for cellular therapy of cancer. Tissue Antigens 2011, 78:409-415.
4. Vivier E., Ugolini S., Blaise D., Chabannon C., Brossay L. Targeting natural killer cells and natural killer T cells in cancer. Nat Rev Immunol 2012, 12:239-252.
5. Basset C., Holton J., O'Mahony R., Roitt I. Innate immunity and pathogen-host interaction. Vaccine 2003, 21(Suppl. 2):S12-S23.
6. Beutler B. Innate immune responses to microbial poisons: discovery and function of the toll-like receptors. Annu Rev Pharmacol Toxicol 2003, 43:609-628.
7. Rosenberg B., Juckett D.A., Aylsworth C.F., Dimitrov N.V., Ho S.C., Judge J.W., et al. Protein from intestinal Eimeria protozoan stimulates IL-12 release from dendritic cells, exhibits antitumor properties in vivo and is correlated with low intestinal tumorigenicity. Int J Cancer 2005, 114:756-765.
8. Appledorn D.M., Aldhamen Y.A., Depas W., Seregin S.S., Liu C.J., Schuldt N., et al. A new adenovirus based vaccine vector expressing an Eimeria tenella derived TLR agonist improves cellular immune responses to an antigenic target. PloS One 2010, 5:e9579.
9. Gowen B.B., Judge J.W., Wong M.H., Jung K.H., Aylsworth C.F., Melby P.C., et al. Immunoprophylaxis of Punta Toro virus (Phlebovirus, Bunyaviridae) infection in hamsters with recombinant Eimeria profilin-like antigen. Int Immunopharm 2008, 8:1089-1094.
10. Gowen B.B., Smee D.F., Wong M.H., Judge J.W., Jung K.H., Bailey K.W., et al. Recombinant Eimeria protozoan protein elicits resistance to acute phlebovirus infection in mice but not hamsters. Antimicrob Agents Chemother 2006, 50:2023-2029.
11. Seregin S.S., Aldhamen Y.A., Appledorn D.M., Aylsworth C.F., Godbehere S., Liu C.J., et al. TRIF is a critical negative regulator of TLR agonist mediated activation of dendritic cells in vivo. PloS One 2011, 6:e22064.
12. Yarovinsky F., Zhang D., Andersen J.F., Bannenberg G.L., Serhan C.N., Hayden M.S., et al. TLR11 activation of dendritic cells by a protozoan profilin-like protein. Science 2005, 308:1626-1629.
13. Tabeta K., Georgel P., Janssen E., Du X., Hoebe K., Crozat K., et al. Toll-like receptors 9 and 3 as essential components of innate immune defense against mouse cytomegalovirus infection. Proc Natl Acad Sci USA 2004, 101:3516-3521.
14. Zhang D., Zhang G., Hayden M.S., Greenblatt M.B., Bussey C., Flavell R.A., et al. A toll-like receptor that prevents infection by uropathogenic bacteria. Science 2004, 303:1522-1526.
15. Rader J.S., Aylsworth C.F., Juckett D.A., Mutch D.G., Powell M.A., Lippmann L., et al. Phase I study and preliminary pharmacology of the novel innate immune modulator rBBX-01 in gynecologic cancers. Clin Cancer Res 2008, 14:3089-3097.
16. Seregin S.S., Hartman Z.C., Appledorn D.M., et al. Novel adenovirus vectors "capsid-displaying" a human complement inhibitor. J Innate Immunity 2010, 2:353-359.
17. Seregin S.S., Aldamen Y.A., Appledorn D.M., Hartman Z.C., Schuldt N.J., Scott J., et al. Adenovirus caspid-display of the retro-oriented human complement inhibitor DAF reduces Ad vector-triggered immune responses in vitro and in vivo. Blood 2010, 116:1669-1677.
18. Aldhamen Y.A., Appledorn D.M., Seregin S.S., Liu C.J., Schuldt N.J., Godbehere S., et al. Expression of the SLAM family of receptors adapter EAT-2 as a novel strategy for enhancing beneficial immune responses to vaccine antigens. J Immunol 2011, 186:722-732.
19. Aldhamen Y.A., Seregin S.S., Schuldt N.J., Rastall D.P., Liu C.J., Godbehere S., et al. Vaccines expressing the innate immune modulator EAT-2 elicit potent effector memory T lymphocyte responses despite pre-existing vaccine immunity. J Immunol 2012, 189:1349-1359.
20. Hwang I., Zhang T., Scott J.M., Kim A.R., Lee T., Kakaria T., et al. Identification of human NK cells that are deficient for signaling adaptor FcRg and specialized for antibody-dependent immune functions. Inter Immunol 2012, 24:793-802.
21. Seregin S.S., Appledorn D.M., McBride A.J., Schuldt N.J., Aldhamen Y.A., Voss T., et al. Transient pretreatment with glucocorticoid ablates innate toxicity of systemically delivered adenoviral vectors without reducing efficacy. Mol Ther 2009, 17:685-696.
22. Maruyama K., Selmani Z., Ishii H., Yamaguchi K. Innate immunity and cancer therapy. Int Immunopharmacol 2011, 11:350-357.
23. Koblansky A.A., Jankovic D., Oh H., Hieny S., Sungnak W., Mathur R., et al. Recognition of profilin by toll-like receptor 12 is critical for host resistance to Toxoplasma gondii. Immunity 2013, 38:119-130.
24. Pegram H.J., Andrews D.M., Smyth M.J., Darcey P.K., Kershaw M.H. Activating and inhibitory receptors of natural killer cells. Immunol Cell Biol 2005, 89:216-224.
25. Williams A.P., Bateman A.R., Khakoo S.I. Hanging in the balance: KIR and their role in disease. Mol Interv 2005, 5:226-240.
26. Lanier L.L. NK cell recognition. Annu Rev Immunol 2005, 23:225-274.
27. Yokoyama W.M., Kim S. Licensing of natural killer cells by self-major histocompatibility complex class I. Immunol Rev 2006, 214:143-154.
28. Parsons M.S., Zipperlen K., Gallant M., Grant M. Killer cell immunoglobulin-like receptor 3DL1 licenses CD16-mediated effector functions of natural killer cells. J Leukoc Biol 2010, 88:905-912.
29. Rathinam V.A.K., Vanaja S.K., Fitzgerald K.A. Regulation of inflammasome signaling. Nat Immunol 2012, 13:333-342.
30. Franchi L., Munoz-Planillo R., Nunez G. Sensing and reacting to microbes through the inflammasomes. Nat Immunol 2012, 13:325-332.
31. Janeway C.A., Medzhitov R. Innate immune recognition. Annu Rev Immunol 2002, 20:197-216.
32. Gerosa F., Baldani-Guerra B., Nisii C., Marchesini V., Carra G., Trinchieri G. Reciprocal activating interaction between natural killer cells and dendritic cells. J Exp Med 2002, 195:327-333.
33. Shanker A., Marincola F.M. Cooperativity of adaptive and innate immunity: implications for cancer therapy. Cancer Immunol Immunother 2011, 60:1061-1074.
34. Iwasaki A., Medzhitov R. Regulation of adaptive immunity by the innate immune system. Science 2010, 327:291-295.
35. Lee S.C., Srivastava R.M., Lopez-Albaitero A., Ferrone S., Ferris R.L. Natural killer (NK): dendritic cell (DC) cross talk induced by therapeutic monoclonal antibody triggers tumor antigen-specific T cell immunity. Immunol Res 2011, 50:248-254.
36. Chalifour A., Jeannin P., Gauchat J.F., Blaecke A., Malissard M., N'Guyen T., et al. Direct bacterial protein PAMP recognition by human NK cells involves TLRs and triggers alpha-defensin production. Blood 2004, 104:1778-1783.
37. Hornung V., Rothenfusser S., Britsch S., Krug A., Jahrsdorfer B., Giese T., et al. Quantitative expression of toll-like receptor 1-10 mRNA in cellular subsets of human peripheral blood mononuclear cells and sensitivity to CpG oligodeoxynucleotides. J Immunol 2002, 168:4531-4537.
38. Tsujimoto H., Uchida T., Efron P.A., Scumpia P.O., Verma A., Matsumoto T., et al. Flagellin enhances NK cell proliferation and activation directly and through dendritic cell-NK cell interactions. J Leukoc Biol 2005, 78:888-897.